Archer Materials (ASX:AXE) partnered with Canadian medical device company Hylid Diagnostics to develop a potassium measurement product for testing chronic kidney disease in its Biochip project, according to a Monday filing with the Australian bourse.
The partnership will use the company's potassium sensing technology and Hylid Diagnostics' blood hemolysis sensor technology to develop a prototype cartridge system, the filing said.
The companies are developing a detailed work plan for the next few months, according to the filing.
Archer Materials shares fell 5% in midday trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.